Focused On-demand Library for Poly(A) RNA polymerase GLD2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q6PIY7

UPID:

GLD2_HUMAN

Alternative names:

PAP-associated domain-containing protein 4; Terminal nucleotidyltransferase 2; Terminal uridylyltransferase 2

Alternative UPACC:

Q6PIY7; Q86WZ2; Q8N927

Background:

Poly(A) RNA polymerase GLD2, also known as PAP-associated domain-containing protein 4, Terminal nucleotidyltransferase 2, and Terminal uridylyltransferase 2, is a cytoplasmic enzyme. It specializes in adding AMP monomers to the 3'-end of specific RNAs, creating a poly(A) tail. This process is crucial for the stabilization and activity of certain cytoplasmic mRNAs and miRNAs, distinguishing it from canonical nuclear poly(A) RNA polymerases.

Therapeutic significance:

Understanding the role of Poly(A) RNA polymerase GLD2 could open doors to potential therapeutic strategies.